2028 Communication Documentation 
Putting Patients First Blog
JUNE 26, 2025
Inclusion of Part B Drugs: Scope, Challenges, and Opportunities The addition of provider-administered therapies covered under Medicare Part B to the IPAY 2028 cycle introduces a fundamentally different reimbursement and care delivery context than that of pharmacy-dispensed Part D drugs.
European Pharmaceutical Review
APRIL 10, 2025
In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. billion Global concerns surrounding PFAS, or per- and polyfluoroalkyl substances, are due to their well-documented effects on human health and the environment. There is worldwide concern around the use of PFAS.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 27, 2023
billion by 2028. Regulatory documentation including a materials traceability report is provided and an extractables report is available upon request. Genomic medicine development was ranked as the top industry trend for 2023 in a survey of 198 GlobalData Pharma clients and prospects conducted between October and November 2022.
Putting Patients First Blog
FEBRUARY 11, 2025
The NHC also emphasizes the importance of clear communication and transition planning to minimize disruptions. The NHC encourages CMS to provide regular updates on guidance documents and implementation progress to keep stakeholders informed and responsive to emerging challenges. 3 American Medical Association.
Expert insights. Personalized for you.
Let's personalize your content